Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM) Stock Price, News & Analysis

Company Overview

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Key Stats

• Today's Range: C$0.29 to C$0.29
• 50-Day Range: C$0.29 to C$0.29
• 52-Week Range: C$0.29 to C$1.50
• Volume: 4,800 shs
• Average Volume: 2,858 shs
• Market Capitalization: C$36.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: CVE:ZOM
• CIK: N/A
• Web: www.zomedica.com
• Phone: 734-369-2555
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 4.91
• Current Ratio: 15.31
• Quick Ratio: 15.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.05 per share
• Price / Cash Flow: 5.38
• Book Value: C$0.05 per share
• Price / Book: 5.82

Miscellaneous

• Outstanding Shares: 128,872,000
• Free Float: N/A
• Market Cap: C$36.73 million
• Optionable: Not Optionable
• Beta: N/A